Novel therapies for chronic myelogenous leukemia

Balkrishna N. Jahagirdar, Jeffrey S. Miller, Arun Shet, Catherine M. Verfaillie

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenous leukemia, and immune mechanisms play an important role in control of this disease. Understanding of the molecular pathogenesis of chronic myelogenous leukemia has led to the development of several novel therapies, which can be broadly divided into therapies based on 1) inhibition of the BCR-ABL oncogene expression, 2) inhibition of other genes important to the pathogenesis of chronic myelogenous leukemia, 3) inhibition of BCR-ABL protein function, and 4) immunomodulation. We have systematically reviewed each of these novel therapeutic approaches in this article.

Original languageEnglish (US)
Pages (from-to)543-556
Number of pages14
JournalExperimental Hematology
Issue number5
StatePublished - May 2001


Dive into the research topics of 'Novel therapies for chronic myelogenous leukemia'. Together they form a unique fingerprint.

Cite this